ScholarLens Back to search
1990•Journal of Clinical Laboratory AnalysisRequires access

Effect of azidothymidine on soluble cd4 levels in patients with aids or aids‐related complex

Mohan M. Reddy, Michael H. Grieco, Morton A. Vodian

Open publisher page 4 citations

Abstract

Circulating soluble CD4 (sCD4) levels were measured in 20 patients (11 with the acquired immunodeficiency syndrome [AIDS] and 9 with AIDS-related complex [ARC]) treated with azidothymidine (AZT) and in 12 patients (nine with AIDS and three with ARC) who were in the placebo group. The mean CD4 level in the AZT treatment group at baseline was 41 +/- 12 (SEM) U/ml. After 4 wk of treatment, the mean level decreased to 23 +/- 5; it was 29 +/- 10, 31 +/- 14, and 21 +/- 5 at 8, 12, and 16 wk of therapy, respectively. No significant changes were observed in the placebo group. These results suggest that AZT administration may be associated with reduced sCD4 levels in these patients.

About this research paper

What this paper is about

Circulating soluble CD4 (sCD4) levels were measured in 20 patients (11 with the acquired immunodeficiency syndrome [AIDS] and 9 with AIDS-related complex [ARC]) treated with azidothymidine (AZT) and in 12 patients (nine with AIDS and three with ARC) who were in the placebo group. The mean CD4 level in the AZT treatment group at baseline was 41 +/- 12 (SEM) U/ml. After 4 wk of treatment, the mean level decreased to 23 +/- 5; it was 29 +/- 10, 31 +/- 14, and 21 +/- 5 at 8, 12, and 16 wk of therapy, respectively. No significant changes were observed in the placebo group. These results suggest that AZT administration may be associated with reduced sCD4 levels in these patients.

Why it matters

OpenAlex reports 4 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Circulating soluble CD4 (sCD4) levels were measured in 20 patients (11 with the acquired immunodeficiency syndrome [AIDS] and 9 with AIDS-related complex [ARC]) treated with azidothymidine (AZT) and in 12 patients (nine with AIDS and three with ARC) who were in the placebo group. The mean CD4 level in the AZT treatment group at baseline was 41 +/- 12 (SEM) U/ml. After 4 wk of treatment, the mean level decreased to 23 +/- 5; it was 29 +/- 10, 31 +/- 14, and 21 +/- 5 at 8, 12, and 16 wk of therapy, respectively. No significant changes were observed in the placebo group. These results suggest that AZT administration may be associated with reduced sCD4 levels in these patients.

Key concepts: AIDS-related complex, Placebo, Zidovudine, Arc (geometry), Human immunodeficiency virus (HIV), Medicine, Placebo group, Internal medicine

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Effect of azidothymidine on soluble cd4 levels in patients with aids or aids‐related complex — Research Paper | ScholarLens